Floatz logo

BENZAMIDE, 3-((3-ENDO)-8-(2-((CYCLOHEXYLMETHYL)((2S)-2,3-DIHYDROXY-1-OXOPROPYL)AMINO)ETHYL)-8-AZABICYCLO(3.2.1)OCT-3-YL)-

Lung Cancer

HealthPartners InstituteSmall moleculePhase 2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
65/ 100

Competitive context

303 Active assets in the Lung Cancer cohort.

Asset / SponsorPhaseRating
Carboplatin
SystImmune Inc.
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
University of Vermont
Phase 4BB
PROPOFOL
Kaohsiung Medical University Chung-Ho Memorial Hospital
Phase 4BB
ETOPOSIDE
SystImmune Inc.
Phase 3BB
Nivolumab
University of Chicago
Phase 4BB

View all 50 →

Same molecule, other indications

BENZAMIDE, 3-((3-ENDO)-8-(2-((CYCLOHEXYLMETHYL)((2S)-2,3-DIHYDROXY-1-OXOPROPYL)AMINO)ETHYL)-8-AZABICYCLO(3.2.1)OCT-3-YL)- is also rated in:

malignant pancreatic neoplasmDormant
CCC
Indicative ·
51 / 100
View asset →
cutaneous melanomaDormant
CCC
Indicative ·
48 / 100
View asset →
breast cancerDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →